

July 21, 2024

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
--	---

Dear Sir/Madam,

Subject.: Q1 FY25 Press Release

Please find enclosed a copy of the Press Release for the Quarter ended June 30, 2024.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited

**Parul
Gupta** Digitally signed
by Parul Gupta
Date: 2024.07.21
13:15:11 +05'30'



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-661621

info@rossari.com

www.rossari.com



HOME, PERSONAL CARE AND PERFORMANCE CHEMICALS



TEXTILE SPECIALITY CHEMICALS



ANIMAL HEALTH AND NUTRITION



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg
West, Mumbai, Maharashtra 400078

Rossari Biotech announces Q1 FY25 results

Q1 FY25

Highest Quarterly Performance

- Revenues at Rs. 489.7 Cr, up 19.3% YoY
- EBITDA at Rs. 64.9 Cr, up 12.5% YoY
- PAT at Rs. 34.9 Cr, up 19.5% YoY

Mumbai, July 20, 2024: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended June 30, 2024.

Consolidated: Q1 FY25 performance overview compared with Q1 FY24

- Revenue from operations grew 19.3% to Rs. 489.7 crore as compared to Rs. 410.6 crore
- EBITDA improved by 12.5% to Rs. 64.9 crore from Rs. 57.7 crore
 - o EBITDA margin at 13.3% as against 14.1%
- PAT increased by 19.5% to Rs. 34.9 crore from Rs. 29.2 crore
- EPS (Diluted) stood at Rs. 6.3* as against Rs. 5.3*

Standalone: Q1 FY25 performance overview compared with Q1 FY24

- Revenue from operations stood at Rs. 300.7 crore as against Rs. 258.3 crore, up 16.4%
- EBITDA increased by 13.4% to Rs. 39.8 crore as against Rs. 35.1 crore
 - o EBITDA margin at 13.2% as against 13.6%
- PAT higher by 12.5% to Rs. 24.3 crore as against Rs. 21.6 crore
- EPS (Diluted) stood at Rs. 4.4* as against Rs. 3.9*

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) * EPS not annualized

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We are pleased to report a strong start to the new financial year, with significant Y-o-Y increases in both revenues and profits by 19.3% and 19.4%, respectively. This performance was largely driven by healthy volume growth both in our HPPC and TSC business. AHN business remained stable during the quarter.

The HPPC and TSC divisions achieved a robust growth of 21%, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. By targeting customers in both new and existing geographies, we have delivered a strong performance in the international markets during the current quarter. Going forward, we expect exports to be a key growth vertical, further strengthening our position in the global market.

R&D is a cornerstone of our growth and innovation strategy, strengthening Rossari’s position as a leading solutions provider in the specialty chemicals sector. Our robust R&D capabilities enable us to meet evolving market needs and offer bespoke solutions, driving growth, creating value, and enhancing our reputation for intelligent and sustainable solutions. While commodity chemicals have benefited from global industry trends in the last few years, we see a promising shift where solution providers and formulators with strong R&D capabilities like Rossari will lead the way in creating sustainable value for all stakeholders going forward.

Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. Our growth strategy continues to focus on broadening our customer base, expanding our geographies and prioritizing higher margin products. Our commitment to R&D, particularly in developing new and innovative products, positions us favourably for delivering healthy operational and financial performance going forward.”

Key Developments

Update on the expansion projects at Dahej Facilities

- In the Q2FY24 the Company had announced an expansion of its facility at Dahej by adding up 20,000 MTPA capacity for products related to HPPC in the specialty chemical space, as well as for producing ingredients for its subsidiary companies. Also, to cater to the growing demand in agro chemicals, home and personal care, oil & gas and the pharma sector, the Company had further announced expansion of the Ethoxylation capacity by 30,000 MTPA at the Dahej facility of Unitop Chemicals Private Limited.
- Work on both these projects are progressing as planned. Commissioning is expected to happen, in a phased manner in the current year.

< Ends >

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok

Rossari Biotech Limited
Tel: +91 22 6123 3800
Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain

CDR India
Tel: +91 98330 90434 / 96194 44691
Email: anoop@cdr-india.com /
mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.